Spectrum Pharmaceuticals announced detailed results from ADVANCE, a Phase 3 trial of Rolontis, demonstrating that it was non-inferior to pegfilgrastim in the reduction of duration of severe neutropenia in all four cycles of the study. Rolontis is a novel long-acting granulocyte colony-stimulating factor being studied as a treatment for neutropenia in patients undergoing myelosuppressive cytotoxic chemotherapy. The data released in an abstract as part of the American Society of Clinical Oncology, or ASCO, 2018 Annual Meeting, also showed similar safety profiles between the treatment groups.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.